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1OptumInsight, Eden Prairie, MN, USA; 2Amgen, Inc., Thousand Oaks, CA, USAA B S T R A C TObjective: To assess the impact of osteoporosis on health care costs
for patients with chronic disease (CD): cardiovascular disease (CVD),
chronic obstructive pulmonary disease (COPD), depression, diabetes
mellitus (DM), or two or more of these CDs. Methods: This retro-
spective analysis included commercially insured or Medicare Advant-
age male and female members aged 50 years or older with medical
and pharmacy beneﬁts who had evidence of osteoporosis and/or one
of the CDs during the identiﬁcation period (January 1, 2007, to October
31, 2009). Cohorts were deﬁned by the presence or absence of
osteoporosis and CD (osteoporosis ONLY, CD ONLY, and CD plus
osteoporosis) and, for osteoporosis cohorts, by incident (recent diag-
nosis) or prevalent osteoporosis (long-standing). Primary outcome
was total health care costs during 1-year follow-up. Costs, adjusted
for baseline characteristics, were analyzed with a generalized linear
model with log link and gamma distribution. Results: Of the 494,160
patients, the majority had evidence of CD with or withoutsee front matter Copyright & 2014, International S
r Inc.
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ndence to: Sarah W. Thayer, OptumInsight, 425 Mosteoporosis: CVD (54%), two or more CDs (24%), DM (8%), depres-
sion (4%), COPD (1%); 9% had osteoporosis ONLY. The range of
actual mean costs was as follows: CD ONLY, $8,377 (CVD) to
$12,801 (two or more CDs); CD plus incident osteoporosis, $15,696
(CVD) to $23,860 (two or more CDs); CD plus prevalent osteoporosis,
$10,038 (CVD) to $17,997 (two or more CDs). Compared with CD
ONLY, baseline-adjusted costs were 66% (two or more CDs) to
91% (DM) higher for CD plus incident osteoporosis and 13% (CVD)
to 23% (depression) higher for CD plus prevalent osteoporosis
(P o 0.001). Conclusions: The burden of osteoporosis in patients
with CD is signiﬁcant, particularly for patients with newly diagnosed
osteoporosis.
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Nearly half of the US population has at least one chronic
condition, and more than one in four individuals have two or
more chronic conditions [1,2]. More than 80% of health care
expenditures are attributable to individuals with chronic diseases
(CDs) [2]. In 2009, diabetes, heart disease, mental disorders, and
pulmonary conditions were among the most costly conditions in
the United States: health care expenditures ranged from $51
billion (diabetes mellitus [DM]) to $107 billion (heart disease) [3].
Health care costs rise in proportion to comorbidity burden: on
average, patients with two chronic conditions incur costs approx-
imately double the costs of patients with one chronic condition
[2,4]. The incremental burden of comorbidity poses a substantial
challenge to affected individuals and their clinicians [5]. Most
clinical guidelines focus on single conditions, and few offer
treatment-speciﬁc recommendations for comorbid conditions
[5,6]. Efforts to manage health care spending will require an
increased focus on comorbidities and, in particular, conditions
that are preventable [1].
Osteoporosis, a systemic, chronic disease characterized by
decrements in bone mass and bone quality, predisposes affected
individuals to a higher risk of fracture [7]. Approximately 75% of
the individuals diagnosed with osteoporosis are women [8]. The
future burden of osteoporosis is heavily dependent on the 34million men and women who have low bone mass that has not
yet progressed to osteoporosis according to diagnostic criteria [9].
The estimated prevalence of osteoporosis in the United States for
individuals aged 50 years is 10 million [9], and it is predicted to
rise primarily because of changing population demographics [10].
Because the prevalence of osteoporosis increases with age,
the population of older individuals is likely to have other chronic
conditions [6]. Osteoporosis may exacerbate the CD, and the CD
may elevate the risk of fracture. Comorbid heart disease and
chronic obstructive pulmonary disease (COPD) are associated
with a higher risk of fracture in women with osteoporosis [11].
Inadequate metabolic control of DM may reduce bone density
status [12], and standard fracture risk algorithms underestimate
the risk in older individuals with type 2 DM [13]. Osteoporosis has
been linked to a higher thrombotic risk in patients with coronary
artery disease [14], and depressed patients are more prone to
falling, increasing the risk of fracture [15]. In these individuals
with comorbid disease and osteoporosis, the complexity of their
care will likely be increased.
Costs associated with fracture are estimated to rise in the
United States from $19.6 billion (2005) to $25.2 billion (2025) [16].
These estimates do not include the total burden of osteoporosis-
related fractures such as disability, impaired quality of life [17,18],
and excess mortality [19]. Estimates of the mean excess costs
attributable to osteoporotic fracture are substantial, as high asociety for Pharmacoeconomics and Outcomes Research (ISPOR).
arket Street, Floor 15, San Francisco, CA 94105.
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However, studies that estimate the health care cost burden in
patients with osteoporosis and common CDs are lacking. The
objective of this study was to assess real-world health care
expenditures for patients with osteoporosis, alone or in combi-
nation with four CDs that are of considerable interest to clini-
cians and health care payers due to their cost and/or health care
resource utilization burden: COPD, cardiovascular disease (CVD)
with a chronic component, DM, and depression. Costs were
captured by stage of osteoporosis: newly identiﬁed (incident)
osteoporosis and prevalent. We hypothesized that osteoporosis
would add signiﬁcant costs to the management of patients with
comorbid disease.Methods
Design and Data Source
This retrospective analysis captured eligibility, medical, and
pharmacy data from a geographically diverse, national health
claims database with the greatest concentration in the South and
Midwest census regions. In 2009, this database contained infor-
mation on approximately 13.3 million individuals with both
medical and pharmacy beneﬁts under commercial or Medicare
Advantage plans. No identiﬁable protected health information
was extracted or accessed during the course of the study.
Pursuant to the Health Insurance Portability and Accountability
Act, the use of de-identiﬁed data does not require institutional
review board approval or waiver [21].
The study spanned two consecutive periods, a 2-year baseline
period and a 1-year follow-up period, separated by the index date.Fig. 1 – Sample selection and cohort assignment. CD, chronic di
cardiovascular disease; DEP, depression; DM, diabetes mellitus;
established during the identiﬁcation period. Incident OP ONLY a
prevalent OP ONLY and CD plus prevalent OP: a randomly chos
chosen service date with evidence of CD of interest. †No evidenc
years of the baseline period. §CD cohorts (except two or more C
period. ||Evidence of OP in both years of the baseline period.Data from both years of the baseline period were used to
establish disease prevalence; data from the second baseline year
were used to characterize patients’ demographic and clinical
characteristics. All data were collected from January 1, 2005,
through October 31, 2010.
Patient Identiﬁcation
The study sample selection, cohorts, and index date assignment
are shown in Figure 1; applicable diagnostic codes, procedure
codes and medications for the inclusion criteria, and cohort
assignment are given in the appendix available in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2013.11.004. In brief, all patients were commercial or Medicare
Advantage enrollees with medical and pharmacy beneﬁts, and
had evidence of osteoporosis and/or a CD of interest (COPD, CVD,
depression, type 1 or type 2 DM) during the identiﬁcation (ID)
period (January 1, 2007, to October 31, 2009). Inclusion also
required continuous enrollment in the health plan with medical
and pharmacy beneﬁts for 2 years preindex and 1 year postindex.
Patients with evidence of any of the following conditions during
the baseline or follow-up period were excluded: Paget’s disease of
the bone and other osteitis deformans and osteopathies, osteo-
genesis imperfecta, hypercalcemia, malignant cancer, and
human immunodeﬁciency virus; individuals receiving preventive
treatment for breast cancer were also excluded.
Cohort Assignment
Disease-speciﬁc algorithms were used to assign patients to
cohorts distinguished by the presence or absence of evidence of
osteoporosis and the four CDs of interest. The osteoporosis ONLYsease; COPD, chronic obstructive pulmonary disease; CVD,
ID, identiﬁcation; OP, osteoporosis. *Index dates were
nd CD plus incident OP: the ﬁrst date with evidence of OP;
en service date with evidence of OP. CD ONLY: a randomly
e of CD in the 2-year baseline period. ‡Evidence of CD in both
Ds) are mutually exclusive of other CD during the baseline
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year baseline or ID period and at least one claim during the ID
period representing one or more of the following: 1) a diagnostic
code for osteoporosis (inpatient or outpatient setting), 2) two or
more osteoporosis medication claims, and 3) diagnostic or pro-
cedure code indicating a closed fracture (inpatient or outpatient
setting). The osteoporosis ONLY cohort was further stratiﬁed by
the presence or absence of osteoporosis in the baseline period.
The incident osteoporosis stratum comprised patients with
osteoporosis during the ID period but not the 2-year baseline
period. The prevalent stratum required evidence of osteoporosis
during the ID period and, to ensure long-standing disease, both
years of the baseline period.
There were ﬁve CD cohorts: COPD, CVD, depression, DM, and
two or more of these CDs. Inclusion in the CVD cohort required
evidence of a chronic component (cerebrovascular, hypertensive,
ischemic, and/or peripheral arterial diseases). The ﬁve CD cohorts
required the presence of the speciﬁc CD(s) during the ID period
and, to demonstrate chronicity, both years of the baseline period.
The four single CD cohorts were mutually exclusive. For example,
patients in the COPD cohort had no evidence of CVD, depression,
or DM during either year of the baseline period. The CD cohorts
were further categorized by the presence or absence of osteopo-
rosis. The CD ONLY cohort comprised patients with no evidence
of osteoporosis during the 2-year baseline or ID period. The CD
with osteoporosis cohort was stratiﬁed by the presence of
incident or prevalent osteoporosis using the same criteria to
deﬁne incident and prevalent osteoporosis as were used for the
osteoporosis ONLY cohort.
Measures
The primary outcome was all-cause total health care costs,
computed as the combined health plan and patient-paid
amounts, for medical services (ambulatory [physician ofﬁce and
outpatient clinic visits], emergency room visits, inpatient stays,
long-term care visits, and other costs) and pharmacy claims.
Costs were adjusted by the Consumer Price Index to 2010 dollars
[22]. Baseline characteristics, including region of health plan
enrollment and patients’ demographic and clinical character-
istics, were captured in the year before the index date. A modiﬁed
Quan-Charlson comorbidity score [23] was calculated from med-
ical claims data. This index contains 17 comorbidity categories
deﬁned with medical codes and serves as a proxy for burden of
comorbidity. Because of the comparison of cohorts with different
CDs, the score was modiﬁed to exclude comorbidities inherent in
the algorithms used to deﬁne CDs: CVD, chronic pulmonary
disease, DM without and with complication, and peripheral
vascular disease. The top Agency for Health Research and Quality
comorbidities [24] identiﬁed in the sample were also recorded:
eye disorders, intervertebral disc disorders and other back prob-
lems, nontraumatic joint disorders, other connective tissue dis-
ease, respiratory infections, spondylosis, and urinary system
diseases. Baseline health care utilization was characterized by
the number of ambulatory visits and binary variables for the
occurrence of an emergency room visit, inpatient stay, and long-
term care visit. For the DM cohort, the type of diabetes (type 1 or
type 2) and number of unique medications were also captured.
Statistical Analyses
The effect of osteoporosis within each CD cohort was assessed
separately for the incident and prevalent osteoporosis strata.
Differences between each CD and osteoporosis versus CD ONLY
and between CD and osteoporosis versus osteoporosis ONLY
were analyzed by using the t-test (e.g., continuous baseline
variables, modiﬁed Quan-Charlson comorbidity score, and all-cause costs during follow-up) and the chi-square test (propor-
tions). Follow-up costs, adjusted for baseline characteristics, were
modeled separately by CD and by incident and prevalent osteo-
porosis strata with a general linear model with log link and
gamma distribution. Because of the potential for skewing,
adjusted costs were modeled by using Blough’s formulation
[25]. Baseline adjustment variables were age, sex, region of health
plan enrollment, modiﬁed Quan-Charlson comorbidity score,
health care utilization, Agency for Health Research and Quality
binary variables described above, and, for the DM cohort only,
type 1 or type 2 DM and count of unique medications. The
reference group was the CD ONLY cohort. All analyses were
conducted by using SAS 9.1 (SAS, Cary, NC) and Stata version 10.1
(StataCorp, College Station, TX).Results
Sample Selection and Baseline Characteristics
Of the 3,547,415 patients who met enrollment, age, osteoporosis,
and/or CD criteria during the ID period, 494,160 (13.9%) patients
met cohort inclusion criteria (Fig. 1). Most of the patients were in
the CVD cohort (N ¼ 265,677, 54%) followed by multiple CDs (N ¼
119,861, 24%), osteoporosis (N ¼ 42,380, 9%), DM (N ¼ 41,842, 8%),
and depression (N ¼ 17,751, 4%). Across cohorts, the mean age
was 64 years and 53% of the patients were women (Table 1).
Within the CD cohorts, 14% (DM) to 33% (COPD) of the patients
also had incident or prevalent osteoporosis. Patients with CD plus
incident or prevalent osteoporosis were generally older and had
mostly higher comorbidity scores than did patients with CD
ONLY or osteoporosis ONLY. There was a pattern for a higher
proportion of women in the CD plus osteoporosis cohorts than in
the CD ONLY cohorts but a lower proportion of women in the CD
plus osteoporosis cohorts than in the osteoporosis ONLY cohort.
Across cohorts, most patients had commercial insurance cover-
age (79.5%). A higher proportion of patients with CD plus
osteoporosis were in Medicare Advantage plans compared with
CD ONLY or osteoporosis ONLY patients.
Actual Health Care Costs
Total all-cause costs during follow-up, including medical and
pharmacy cost components, are shown in Figure 2 by CD cohort
and osteoporosis strata. Mean total costs for CD ONLY cohorts
ranged from $8,377 (CVD) to $12,801 (two or more CDs). For patients
with CD with incident osteoporosis, the range in mean costs was
$15,696 (CVD) to $23,860 (two or more CDs); costs were 1.8 (COPD) to
2.1 (DM) times higher than for patients with CD ONLY (Po 0.001, all
cohorts). Compared with mean costs for patients with incident
osteoporosis ONLY ($9,330), patients with CD plus incident osteopo-
rosis incurred 1.7 (CVD) to 2.6 (Z2 CDs) times higher mean costs (Po
0.001, all cohorts). Mean costs for patients with CD plus prevalent
osteoporosis ranged from $10,038 (CVD) to $17,997 (two or more CDs)
and were 20% (CVD) to 47% (depression) higher than for patients
with CD ONLY (P o 0.001, all cohorts). Mean costs for CD plus
prevalent osteoporosis were 1.9 to 3.3 times higher than mean costs
for prevalent osteoporosis ONLY ($5,377) (P o 0.001, all cohorts).
Adjusted Health Care Costs
Baseline-adjusted total all-cause costs during follow-up, by CD
cohort and osteoporosis strata, are given in Table 2. The cost
ratios represent the β coefﬁcient for the modeled results.
Adjusted costs based on these models are shown in Figure 3.
For the incident osteoporosis stratum, total costs were 66% (two
or more CDs) to 91% (DM) higher in the CD plus osteoporosis
cohorts than in CD ONLY cohorts (P o 0.001, all cohorts). Costs
Table 1 – Baseline patient characteristics by chronic disease cohort and osteoporosis incident and prevalent strata.
Characteristic OP ONLY Chronic disease
COPD CVD DEP DM Z2 CDs
ONLY þOP ONLY þOP ONLY þOP ONLY þOP ONLY þOP
Incident osteoporosis
N 24,402 4,439 948 208,573 27,316 13,538 2,102 36,123 3,221 96,038 13,309
Age (y), mean  SD 58.5  7.4 66.5  10.0 67.9  9.9*,‡ 64.0  10.2 67.9  11.1*,† 56.5  6.5 58.2  7.5* 61.3  8.9 64.1  10.2*,† 65.0  9.9 68.5  10.5*,†
Modiﬁed Quan-Charlson score,
mean  SD
0.13  0.45 0.45  0.89 0.46  0.85† 0.39  0.84 0.50  0.94*,† 0.19  0.57 0.28  0.71*,† 0.26  0.70 0.39  0.85*,† 0.61  1.08 0.80  1.22*,†
Females, % 82.1 38.9 69.4*,† 41.2* 73.4*,† 65.9 86.4*,† 38.7 70.7*,† 40.6 68.9*,†
Coverage, %
Commercial 94.5 67.9 65.9‡ 80.7 70.4*,† 94.2 90.6*,† 88.6 80.5*,† 74.9 62.9*,†
Medicare Advantage 5.5 32.1 34.1‡ 19.4 29.6*,† 5.8 9.4*,† 11.4 19.5*,† 25.1 37.1*,†
Region, %
Northeast 10.8 10.8 11.4 10.6 12.5*,† 13.6 14.4† 8.7 10.5* 10.1 11.7*,‡
Midwest 24.0 34.1 29.4†,§ 30.1 28.4*,† 33.5 30.3†,§ 27.8 24.5* 31.3 30.2†,§
South 47.5 42.4 44.0‡ 47.4 46.9 37.9 40.9†,§ 48.0 49.5‡ 47.8 47.4
West 17.7 12.8 15.2‡,§ 11.9 12.2† 15.1 14.5† 15.5 15.5‡ 10.8 10.6†
Prevalent osteoporosis
N 17,978 4,439 1,262 208,573 29,788 13,538 2,111 36,123 2,498 96,038 10,514
Age (y), mean  SD 61.6  7.9 66.5  10.0 70.5  9.8*,† 64.0  10.2 71.6  10.4*,† 56.5  6.5 61.6  7.9* 61.3  8.9 66.9  10.3*,† 65.0  9.9 71.4  10.1*,†
Modiﬁed Quan-Charlson score 0.16  0.51 0.45  0.89 0.52  0.94†,§ 0.39  0.84 0.52  0.95*,† 0.19  0.57 0.36  0.79*,† 0.26  0.70 0.44  0.89*,† 0.61  1.08 0.85  1.22*,†
Females, % 97.2 38.9 87.8*,† 41.2 92.3*,† 65.9 95.9*,† 38.7 90.4*,† 40.6 88.2*,†
Coverage, %
Commercial 93.8 67.9 65.4† 80.7 69.1*,† 94.2 87.8*,† 88.6 81.5*,† 74.9 63.5*,†
Medicare Advantage 6.2 32.1 34.6† 19.4 30.9*,† 5.8 12.2*,† 11.4 18.5*,† 25.1 36.5*,†
Region, %
Northeast 9.4 10.8 10.5 10.6 13.9*,† 13.6 14.7† 8.7 11.6*,† 10.1 14.6*,†
Midwest 25.7 34.1 31.1†,§ 30.1 28.1*,† 33.5 28.9*,‡ 27.8 23.4*,‡ 31.3 29.1*,†
South 45.9 42.4 42.6‡ 47.4 43.2*,† 37.9 42.3*,‡ 48.0 46.4 47.8 43.7*,†
West 19.0 12.8 15.8‡,§ 11.9 14.5*,† 15.1 14.3† 15.5 18.7* 10.8 12.7*,†
CD, chronic disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DEP, depression; DM, diabetes mellitus; OP, osteoporosis.
* P value for CD þ OP vs. CD ONLY o 0.001.
† P value for CD þ OP vs. OP ONLY o 0.001.
‡ P value for CD þ OP vs. OP ONLY o 0.05.
§ P value for CD þ OP vs. CD ONLY o 0.05.
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Fig. 2 – Actual all-cause total health care costs by CD cohort and OP incident and prevalent strata during 1-year follow-up. All
comparisons of each CD þ OP cohort vs. each CD ONLY cohort (Po 0.001). All comparisons of each CD þ OP cohort vs. OP ONLY
cohort (P o 0.001). CD, chronic disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DEP,
depression; DM, diabetes mellitus; OP, osteoporosis.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 3 – 5 0 47were higher for the incident osteoporosis ONLY cohort than for
the CD ONLY cohorts for CVD (32%, P o 0.001), depression (31%,
P o 0.001), and DM (66%, P o 0.001) but 5% lower than the two or
more CDs ONLY cohort (P o 0.001). There was no difference in
costs between CD ONLY and incident osteoporosis ONLY for the
COPD cohort (P ¼ 0.80). In the prevalent osteoporosis stratum,
cohorts with CD plus osteoporosis had 13% to 23% higher costs
than the CD ONLY cohorts (P o 0.001). The opposite pattern was
evident for the prevalent osteoporosis ONLY cohort: costs were
lower than for each CD ONLY cohort by 11% (DM ONLY) to 43%
(two or more CDs ONLY) (P o 0.001).Discussion
The results of this study reveal the substantial burden of
osteoporosis in patients with four common CDs that are of
signiﬁcant interest to payers. For patients with one or more of
these comorbidities, concomitant osteoporosis increased
adjusted costs by 66% to 91% in the incident stratum and by
13% to 23% in the prevalent stratum compared with costs of the
CD(s) alone. The burden of osteoporosis was highest in patients
with two or more CDs. These ﬁndings highlight the need to
aggressively manage osteoporosis to minimize additional burden
for patients who already incur high health care costs. Disease
management programs based on enhanced education, screening,
and treatment of patients with osteoporosis, or at risk of devel-
oping osteoporosis, have been demonstrated to reduce fracture
rates, and the costs of these programs were more than offset by
predicted cost savings associated with the reduction in fractures
[26,27]. Because fracture risk may be elevated in some CDs
[11,12,15], proactive management of osteoporosis under these
conditions will be particularly important to contain costs.
The higher costs of incident osteoporosis compared with
those of prevalent osteoporosis are noteworthy. Our primary
comparisons were for the effect of osteoporosis alone or in
combination with a CD within each osteoporosis stratum and
we did not make formal comparisons between the incident andprevalent strata. Nevertheless, these results suggest that the
burden of osteoporosis is larger in newly diagnosed patients with
existing CD. This may be attributable to a combination of factors.
Clinical management of osteoporosis in the context of comorbid
conditions may be more complex. The initial diagnosis of osteo-
porosis is likely to require additional resource utilization for bone
density screening and ambulatory visits that would not likely
occur or occur as frequently for patients who have already been
diagnosed with osteoporosis. Furthermore, the diagnosis of
osteoporosis may occur in conjunction with or as a result of a
fragility fracture. Excess costs attributable to nonvertebral frac-
ture in the ﬁrst year have been estimated at $5,267, ranging from
$2,607 to $13,334 depending on fracture location [28]. One of the
qualifying criteria for inclusion in an osteoporosis cohort in this
study was a fracture on or after the index date. For patients with
osteoporosis only, a fracture on the index date was the qualifying
event for 34% of the incident group and 7% of the prevalent
group. Excess costs attributable to fragility fracture are poten-
tially avoidable because effective treatments are available [29].
For patients with a chronic condition and no evidence of
osteoporosis, actual total annual health care costs ranged from
$8,377 to $12,801. As expected, patients with multiple CDs incurred
the highest costs ($12,801), followed by patients with COPD ($11,048),
depression ($9,467), DM ($8,570), and CVD ($8,377), respectively.
These values are lower than recent estimates from other research:
COPD, $17,765 to $23,492 [4,30,31]; depression, $10,024 to $17,990
[4,32]; DM, $11,744 [33]. For CVD, we included several conditions with
chronic components and our costs cannot be readily compared with
studies focused on a single condition. Our results for COPD,
depression, and DM may be lower because we included only
patients with prevalent, stable chronic disease, thus excluding
recently diagnosed patients who may incur higher costs around
the time of diagnosis. Furthermore, lower mean costs for our single
CD cohorts would be expected because each cohort is mutually
exclusive and the conditions we examined may cluster [34,35].
This study provides a fuller understanding of the real-world
health care costs associated with osteoporosis in the context of
preexisting comorbidity and addresses a signiﬁcant gap in the
Table 2 – Adjusted cost ratios during 1-y follow-up by chronic disease and osteoporosis incident and prevalent strata.
Reference group: CD ONLY Chronic disease
COPD* CVD† DEP‡ DM§ Z2 CD¶
Cost ratio
(95% CI)
P Cost ratio
(95% CI)
P Cost ratio
(95% CI)
P Cost ratio
(95% CI)
P Cost ratio
(95% CI)
P
Incident osteoporosis
CD þ OP 1.77 (1.54–2.05) o0.001 1.71 (1.67–1.75) o0.001 1.76 (1.61–1.91) o0.001 1.91 (1.78–2.05) o0.001 1.66 (1.61–1.72) o0.001
OP ONLY 1.01 (0.94–1.09) 0.80 1.32 (1.28–1.35) o0.001 1.31 (1.26–1.37) o0.001 1.66 (1.60–1.73) o0.001 0.95 (0.92–0.97) o0.001
Prevalent osteoporosis
CD þ OP 1.20 (1.09–1.33) o0.001 1.13 (1.10–1.15) o0.001 1.23 (1.16–1.32) o0.001 1.19 (1.11–1.27) o0.001 1.19 (1.15–1.23) o0.001
OP ONLY 0.58 (0.54–0.62) o0.001 0.79 (0.77–0.82) o0.001 0.79 (0.77–0.82) o0.001 0.89 (0.85–0.92) o0.001 0.57 (0.56–0.59) o0.001
AHRQ, Agency for Healthcare Research and Quality; CD, chronic disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DEP, depression; DM, diabetes mellitus; OP,
osteoporosis.
* COPD: Male gender, higher comorbidity score, nontraumatic joint disorders (prevalent stratum only), other connective tissue disease (incident OP stratum only), spondylosis and other back
problems, occurrence of an inpatient (IP) stay, emergency room (ER) visit (prevalent OP stratum only), and more ambulatory visits were associated with higher cost ratios.
† CVD: Male gender, higher comorbidity score, AHRQ comorbidities except eye disorders, occurrence of an IP stay, ER visit, long-term care visit, and more ambulatory visits were associated with
higher cost ratios.
‡ DEP: Male gender, higher comorbidity score, nontraumatic joint disorders and other connective tissue disease, spondylosis and other back problems, eye disorders (prevalent OP stratum only),
respiratory infections (prevalent OP stratum only), diseases of the urinary system (prevalent OP stratum only), occurrence of an IP stay, ER visit, long-term care visit (incident OP stratum only),
and more ambulatory visits were associated with higher cost ratios.
§ DM: Male gender, type 1 DM, midwest region (incident OP stratum only), higher comorbidity score, nontraumatic joint disorders, diseases of the urinary system (prevalent OP stratum only),
spondylosis and other back problems (incident OP stratum only), occurrence of an IP stay, ER visit, long-term care visit, and more ambulatory visits were associated with higher cost ratios.
¶ Z2 CDs: Male gender, higher comorbidity score, AHRQ comorbidities except eye disorders, occurrence of an IP stay, ER visit, long-term care visit, and more ambulatory visits were associated
with higher cost ratios.
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Fig. 3 – Adjusted all-cause total health care costs by CD
cohort and OP incident and prevalent strata during 1-year
follow-up. All comparisons of each CD þ OP cohort vs. each
CD ONLY cohort (reference group) (P o 0.001). CD, chronic
disease; COPD, chronic obstructive pulmonary disease; CVD,
cardiovascular disease; DEP, depression; DM, diabetes; OP,
osteoporosis.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 3 – 5 0 49literature. The management of osteoporosis in conjunction with
other comorbidity is resource intensive and adds signiﬁcant
burden to patients, their providers, and health care systems.
Additional research, particularly studies of other prevalent and
costly chronic conditions and in patients with higher comorbid-
ity, is warranted to extend our ﬁndings.
The results of this study should be interpreted in light of
important limitations. Our study is based on administrative claims
data; we used medical and procedures codes in conjunction with
pharmacy claims to identify the study cohorts. A diagnostic code on
a medical claim is not proof positive of a disease, and diagnostic
codes may be missing. We used closed fracture codes as one of the
inclusion criteria for patients with osteoporosis, and it is possible
that some of the fractures were not directly related to osteoporosis.
A pharmacy claim does not guarantee that a medication was taken
or taken as prescribed. Furthermore, patients included in the
osteoporosis cohort based only on pharmacy claims may have been
prescribed the medication for osteoporosis prevention. There were
signiﬁcant imbalances in patients’ baseline demographic and clin-
ical characteristics. Our health care costs are based on multivariate
adjustment for baseline differences but may not have fully
accounted for these differences and/or there may have been other
differences that we could not observe in our database. Our results
are based on a sample of patients with commercial and Medicare
Advantage coverage. Patients with Medicare Advantage may not be
representative of the Medicare population. Furthermore, our sample
included only patients with continuous health plan enrollment for
at least 36 months. Thus, our results are primarily applicable to
patterns of CD and osteoporosis in stable, managed care settings.Conclusions
Osteoporosis, particularly newly identiﬁed osteoporosis, is asso-
ciated with considerable health care cost and a signiﬁcantly
higher burden for patients with COPD, CVD, depression, and/or
DM. Costs were highest for patients with two or more of these
conditions. Results from this study suggest that in patients who
are already being treated for CDs with high cost and/or high
health care resource utilization, osteoporosis can add a signiﬁ-
cant cost burden. In these patients, appropriate treatment and
management of osteoporosis in conjunction with the patients’CDs should be prioritized to improve the overall quality of care
and potentially reduce total health care costs.Acknowledgments
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